North China Pharmaceutical (SHA:600812) received 94.9 million yuan in compensation after the government acquired its plot of land in Shijiazhuang City, Hebei, China, according to a Saturday filing with the Shanghai bourse.
The company will use the funds to reduce relocation and work stoppage losses for the same amount, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments